CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that new clinical and preclinical data from the company’s lead programs will be presented at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna. Agios’ cancer metabolism medicines are being developed in collaboration with Celgene.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
